SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of drug products to extend healthy lifespan. It focuses on developing two novel therapeutic platforms, MyMD-1 and SUPERA-CBD, which aim to treat the causes of disease rather than just addressing the symptoms. MyMD-1 is a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cytokines. SUPERA-CBD is a synthetic derivative of cannabidiol being developed to treat conditions such as epilepsy, chronic pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in New York, NY.

Q/C Technologies Inc.

QCLS is trending due to its strategic shift towards quantum computing with potential applications in energy-efficient blockchain and cryptocurrency, drawing attention from investors. The community is actively discussing the implications of their laser-based processing unit (LPU) technology and its potential to disrupt the crypto and AI industries. Traders are also watching for news and potential partnerships related to its low float and threshold list status.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending due to increased interest in the quantum computing sector, fueled by new deals and government initiatives that have sparked a rally. The community is actively discussing the stock's potential and comparing it to others in the sector like IONQ and QBTS. Some traders point to the company's high valuation relative to revenue, while others remain bullish, citing long-term growth potential and recent contracts.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble Inc is trending due to its strategic partnership with Perplexity AI, aimed at enhancing content discovery and offering a bundled premium subscription. Community discussions highlight the potential integration of AI with crypto, the involvement of key investors like Jeff Bezos, and the possibility of a short squeeze given high short interest. Some investors speculate on the impact of Tether's involvement and the potential for Rumble to gain traction in the AI space.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending due to a Jefferies downgrade, citing overly optimistic iPhone expectations, which has sparked debate among investors about its validity and impact. While some community members view the downgrade as an opportunity to buy, others express concern about Apple's valuation and potential risks related to tariffs. Broader discussions involve Apple's AI strategy, competition in the wearables market, and potential government shutdown impacts.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

QBTS is trending as part of a broader surge in quantum computing stocks, driven by increasing interest and speculation around government contracts and potential big tech partnerships. Community discussions revolve around the company's valuation, short squeeze potential, and its competitive position relative to other quantum firms like RGTI and IONQ. Some investors express concerns about a potential bubble, while others highlight D-Wave's technological advantages and growing real-world applications.

Quantum Computing, Inc. engages in developing novel algorithms and solutions utilizing quantum and quantum-inspired computing to solve difficult problems in various industries. It leverages its expertise in finance, computing, security, mathematics, and physics to develop commercial applications for the financial, security, and government sectors. The company was founded on July 25, 2001 and is headquartered in Hoboken, NJ.

Quantum Computing Inc

Quantum Computing Inc. is trending as it navigates a significant private placement, leading to community discussions around dilution and future growth prospects. While some traders express concerns about the offering's impact, others view it as a strategic move to fund expansion and acquisitions in the burgeoning quantum computing sector, noting the potential for government contracts to boost the stock.

Unusual Machines, Inc. is a development stage technology company, which engages in the provision of drone solutions with a focus on first-person view (FPV) technology. It offers products to entertainment, recreation, and competitive racing industries. The company was founded on July 11, 2019, and is headquartered in Orlando, FL.

Unusual Machines Inc

Unusual Machines, Inc.

Unusual Machines is trending after securing an $800,000 order for drone components from Red Cat, fueling discussions about drone dominance and the company's growth potential. While some community members question if the order size justifies the stock's reaction, others see it as a sign of more substantial contracts to come, especially with increasing government and defense sector interest in drone technology. The community is also closely watching for further developments and partnerships within the drone sector.

Astrotech Corp. engages in the mass spectrometry company that launches, manages and commercializes scalable companies based on its innovative core technology through its wholly-owned subsidiaries. Its business units include 1st Detect, BreathTech, and AgLab. The company was founded in 1984 and is headquartered in Austin, TX.

Astrotech Corp

ASTC is experiencing high volatility and significant volume, leading to a surge in price. The community is actively discussing profit-taking strategies and potential breakout levels. The stock's momentum and low float are key factors driving the current interest.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is trending as community members discuss Needham initiating coverage with a buy rating and a price target of $17, coupled with an $800,000 order for drone components from Unusual Machines (UMAC). Bullish sentiment is fueled by the belief that RCAT's investment thesis is being validated within the unmanned aerial systems sector, anticipating further demand for defense-grade drones. The community speculates on potential catalysts, including government contracts and the company's position in the exploding drone market.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending due to anticipation surrounding multiple data presentations at an upcoming conference, sparking optimism within the community. Investors are discussing the potential impact of these results, particularly on the company's pipeline and market position. Some are speculating about potential M&A activity, while others focus on the potential for a significant price increase based on positive data and the company's overall value.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NVS to Acquire TRML, Add Phase III Cardiovascular Drug to Pipeline 

Novartis is set to acquire Tourmaline Bio for $1.4B, adding late-stage anti-IL-6 candidate pacibekitug to its cardiovascular pipeline.

Shares of Tourmaline Bio (TRML) jumped 58% in the pre-market session on Tuesday after Novartis (NVS) announced that it has agreed to acquire the smaller biopharmaceutical firm.Under the <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.novartis.com/news/media-releases/novartis-acquire-tourmaline-bio-complementing-cardiovascular-pipeline-pacibekitug-treatment-atherosclerotic-cardiovascular-disease-ascvd">deal</a>, Novartis will commence a tender offer to purchase all outstanding shares of Tourmaline common stock through an indirect wholly owned unit. The deal price of $48 per share presents a premium of nearly 59% to Tourmaline’s last closing price and values the company at about $1.4 billion on a fully diluted basis. Following the closing of the tender offer, the unit will merge with Tourmaline, and the company will become an indirect wholly owned subsidiary of Novartis.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/TRML">TRML stock</a> jumped from ‘bearish’ to ‘extremely bullish’ over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.Meanwhile, sentiment around <a href="https://stocktwits.com/symbol/NVS">NVS stock</a> fell from ‘Neutral’ to ‘Bearish territory, while message volume rose from ‘low’ to ‘normal’ levels.Novartis stated that the acquisition includes Tourmaline’s Pacibekitug being developed as a treatment option for atherosclerotic cardiovascular disease or the build-up of fats, cholesterol, and other substances in and on the artery walls. Pacibekitug complements Novartis’ cardiovascular strategy, the company said, while noting that with mid-stage trials of Pacibekitug already well-advanced, the company will acquire a late-stage-ready asset."Inflammation is a major driver of cardiovascular disease, and the team at Tourmaline has made significant progress with this asset. We are excited to bring Pacibekitug into the Novartis portfolio and collaborate with the Tourmaline team to advance its development as we diversify our efforts in cardiovascular care," said Shreeram Aradhye, Chief Medical Officer of Novartis. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; The transaction has been unanimously approved by the Board of Directors of both companies. It is expected to close in the fourth quarter of 2025, subject to the satisfaction or waiver of customary closing conditions. Until the transaction is closed, the two companies will continue to operate as separate, independent entities, Novartis said.TRML stock is up by 49% this year, while NVS stock gained over 32%.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-launches-ai-machine-learning-platform-called-tunelab/chwKTzARdsU">Eli Lilly Launches AI, Machine Learning Platform Called TuneLab For Biotech Companies</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Tourmaline Bio Stock Just Rocketed 58% Pre-Market – Here’s What Happened

Novartis has announced that it has agreed to acquire the biopharmaceutical firm, and the deal price of $48 per share presents a premium of nearly 59% to Tourmaline’s last closing price. 

Equity

Novartis has announced that it has agreed to acquire the biopharmaceutical firm, and the deal price of $48 per share presents a premium of nearly 59% to Tourmaline’s last closing price. 


Wall Street Analysts Predict a 151% Upside in Tourmaline Bio, Inc. (TRML): Here's  What You Should Know

The consensus price target hints at a 151% upside potential for Tourmaline Bio, Inc. (TRML). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Tourmaline Bio (TRML) Receives a Buy from Piper Sandler

In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Tourmaline Bio (TRML Research Report), with a price targ...

The Lustgarten Foundation Appoints Two New Board Members

The Lustgarten Foundation Appoints Two New Board Members The Lustgarten Foundation Appoints Two New Board Members PR Newswire WOODBURY, N.Y., June 13, 2024 Richard Barakat, MD, and Aaron Kantoff join...

Avalo Therapeutics Appoints Biotech Leaders to Board of Directors

Appointments include industry veterans Aaron Kantoff, Jonathan Goldman, and Samantha Truex as Independent DirectorsBoard of Director appointments in conjunction with Avalo's recent acquisition of...

Tourmaline Bio, Inc. (NASDAQ:TRML) Receives $55.60 Consensus Target Price from Analysts

Shares of Tourmaline Bio, Inc. (NASDAQ:TRML - Get Free Report) have earned an average recommendation of "Buy" from the six analysts that are currently covering the firm, Marketbeat reports. Six...

Tourmaline Bio (NASDAQ:TRML) Price Target Increased to $72.00 by Analysts at Jefferies Financial Group

Tourmaline Bio (NASDAQ:TRML  Free Report) had its target price raised by Jefferies Financial Group from $41.00 to $72.00 in a report released on Wednesday morning, Benzinga reports. Jefferies...

Tourmaline Bio (NASDAQ:TRML) Shares Gap Down to $44.67

Tourmaline Bio, Inc. (NASDAQ:TRML  Get Free Report)s share price gapped down prior to trading on Thursday . The stock had previously closed at $44.67, but opened at $29.29. Tourmaline...

Q1 2024 Earnings Estimate for Tourmaline Bio, Inc. Issued By Leerink Partnrs (NASDAQ:TRML)

Tourmaline Bio, Inc. (NASDAQ:TRML  Free Report)  Equities researchers at Leerink Partnrs upped their Q1 2024 earnings per share estimates for shares of Tourmaline Bio in a research...

Tourmaline Bio, Inc. is a late-stage clinical biotechnology company, which engages in the development of medicines for patients with life-altering immune diseases. It offers the TOUR006. The company was founded by Sandeep Kulkarni on September 17, 2021 and is headquartered in New York, NY.

Tourmaline Bio Inc

0 to 25,000

25,000 to 50,000

50,000 to 75,000

75,000 to 100,000

How many jobs did the U.S. add in September? Vote below + drop your exact prediction in the comments. 
 
*Powered by Polymarket

Current Price	$47.89
Prev Close	$47.87
Open	$47.90
Dividend Yield	0.00%
50-Day Moving Average	$31.76
Beta	1.11
Avg. Volume	2.02M
PE Ratio	-13.93

52-Week High	$48.27
52-Week Low	$11.56
Market Capitalization	$1.23B
EPS (Annual)	-$2.89
Price to Book	4.75
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

TRML
Tourmaline Bio Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TRML News

TRML Tourmaline Bio Inc